1Glassman AH. Clinical management of cardiovascular risks during treatment with psychotropic drugs [J].J Clin Psychiatry, 2002, 63 Suppl, 9:12-17. 被引量：1
2Casey DE, Zorn SH. The pharmacology of weigh gain with antipsychotics [J].J Clin Psychiatry, 2001,62 Suppl, 714-10. 被引量：1
3Emsley R, Oosthuizen P. The new and evolving pharmacotherapy of schizophrenia. Psychiat Clin North Am. 2003 ; 26 (1) : 141-163. 被引量：1
4Stimmel GL, Guitierrez MA, Lee V. Ziprasidone: an typical antipsychotic drug for the treatment of schizophrenia[J].Clinical Therapeutics, 2002, 24( 1 ) : 21-37. 被引量：1
5Kaye NS, Ziprasidone augmentation of clozapine in patients[J] .J Cfin Psychiatry, 2003; 64 (2):215-216. 被引量：1
6Wirshing DA, Pierre JM, Erhart SM, et al. Understanding the new and evolving profile of adverse drug effectsin schizophrenia [J].Psychiat Clin North Am. 2003, 26(1 ) : 165-190. 被引量：1
